China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on the Hong Kong Stock Exchange, with further details to be disclosed at a later stage. The proceeds from the IPO will be directed towards the clinical development, regulatory filing, and post-approval studies for its core product, HTD1801, as well as the development of obesity drug HTD1804 and other pipeline products.
Focus on Metabolic and Digestive Diseases
Founded in 2011, HighTide is dedicated to the discovery, development, and commercialization of first-in-class drugs with multiple functions and targets for the treatment of metabolic and digestive diseases. Headquartered in Shenzhen, the company has an impressive pipeline of 5 products covering 9 indications, with 5 of them at clinical stages.
HTD1801: A Potential Global First-in-Class Treatment
Among HighTide’s pipeline, HTD1801 stands out as a potential global first-in-class new molecular entity under development to treat primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), non-alcoholic steatohepatitis (NASH) comorbid with type 2 diabetes mellitus (NASH & T2DM), and T2DM comorbid with non-alcoholic fatty liver disease (T2DM & NAFLD).
Advancements in Clinical Trials
HTD4010, a TLR4 inhibitor, is on the verge of entering Phase II clinical studies, having successfully concluded Phase I studies in NASH. This progress underscores HighTide’s commitment to advancing novel treatments for complex metabolic and digestive diseases.-Fineline Info & Tech
